Hazard Ratios for Venous Thromboembolism According to Changes in Body Weight and Body Mass Index Measured at the Start of the Weight Change Interval.

<p>Subjects with BMI <25 kg/m² and 0–7.4 kg weight gain were used as reference. Age as time-scale, adjusted for sex.</p

Baseline Characteristics of the Study Population Across Categories of Weight Change

<p>Baseline Characteristics of the Study Population Across Categories of Weight Change</p

Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Provoked and Unprovoked Venous Thromboembolism According to Changes in Body Weight, Competing Risk by Cancer and Competing risk by Death Analysis

<p>Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Provoked and Unprovoked Venous Thromboembolism According to Changes in Body Weight, Competing Risk by Cancer and Competing risk by Death Analysis</p

Incidence Rates (IR) and Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Venous Thromboembolism (VTE) According to Changes in Body Weight, Stratified by BMI at the Start of the Weight Change Interval

<p>Incidence Rates (IR) and Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Venous Thromboembolism (VTE) According to Changes in Body Weight, Stratified by BMI at the Start of the Weight Change Interval</p

Crude Incidence Rates (IR) and Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Provoked and Unprovoked Venous Thromboembolism (VTE) According to Changes in Body Weight.

<p>Stratified According to BMI at the start of the weight change interval.</p

Distribution of weight change (in kgs) in the study population

<p>Distribution of weight change (in kgs) in the study population</p

Incidence rates (IRs) and hazard ratios (HRs) for symptomatic venous thromboembolism by categories of platelet count and leukocyte count with 95% confidence intervals; The Tromsø Study 1994–2009.

<p>*10⁹/L.</p>†<p>Person years. Subjects who develop cancer during follow-up are treated as non-cancer subjects until one year prior to the cancer diagnosis.</p>‡<p>Incidence rate per 1000 person years.</p><p>Model 1: Adjusted for age and sex.</p><p>Model 2: Adjusted for age, sex, smoking, body mass index and mean platelet volume.</p><p>Model 3: Model 2+ cancer stage (defined as localized or disseminated disease).</p

Incidence rates (IRs) and hazard ratios (HRs) for symptomatic venous thromboembolism by increasing platelet count with 95% confidence intervals; The Tromsø Study 1994–2009.

<p>*10⁹/L.</p>†<p>Person years. Subjects who develop cancer during follow-up are treated as non-cancer subjects until one year prior to the cancer diagnosis.</p>‡<p>Incidence per 1000 person years.</p><p>Model 1: Adjusted for age and sex.</p><p>Model 2: Adjusted for age, sex, body mass index, smoking, leukocyte count and mean platelet volume.</p><p>Model 3: Model 2+ cancer stage (defined as localized or disseminated disease).</p

Characteristics across categories of platelet count at the time of cancer diagnosis; The Tromsø Study 1994–2009.

<p>*Includes es°phagus, stomach, small intestine, liver, gallbladder and biliary tract.</p><p>SD; standard deviation.</p

WBC count and risk of venous thromboembolism.

<p>Dose–response relationship between WBC count and risk of VTE in cancer and non-cancer subjects obtained by generalized linear regression. The regression models are adjusted for age, sex, BMI, smoking, self-reported diabetes, physical activity and self-reported CVD. The solid lines show HRs and the shaded areas show 95% CIs. Density plots show the distribution of WBC, and white vertical lines indicate 2.5^th, 25^th, 50^th, 75^th and 97.5^th percentiles.</p